Can a glucose monitor boost diabetes remission? new trial aims to find out

NCT ID NCT07157384

Not yet recruiting Disease control Sponsor: LMC Diabetes & Endocrinology Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study will test whether using a continuous glucose monitor (isCGM) helps more people with type 2 diabetes achieve remission compared to standard finger-stick testing. Both groups will follow a low-calorie meal replacement plan and receive diabetes education. The trial aims to enroll 176 adults and will track remission rates after 18-30 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: intermittently scanned continuous glucose monitor (isCGM) device
What this could lead to: If it works, this could show that using a continuous glucose monitor helps more people with type 2 diabetes achieve remission through diet and education.
What could go wrong: This is a relatively small, early-stage trial (176 people) that has not yet started. The remission may not last long-term, and the diet plan is very low-calorie, which can be hard to stick with.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES

Contacts and locations

Locations

LMC Bayview

Toronto, Ontario, M4G 3E8, Canada
LMC Brampton

Brampton, Ontario, Canada
LMC Etobicoke

Etobicoke, Ontario, Canada
LMC Oakville

Oakville, Ontario, Canada
LMC Ottawa

Ottawa, Ontario, Canada
LMC Vaughan

Vaughan, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.